(OTCQB: ADIA), a leader in regenerative medicine through its subsidiary Adia Med, today announced an ambitious expansion of its clinical research pipeline, with plans to launch four to five additional studies throughout 2026
Once-weekly cagrilintide for weight management in people with overweight and obesity: A multicentre, randomised, double-blind, placebo-controlled and active-controlled, dose-finding phase 2 trial
If sleep is a challenge, Does Lack of Sleep Cause Brain Fog
#PharmaIndustry #Semaglutide #GLP1 #HealthcareIndia #Pharmacology #PharmaTrends #DrugDevelopment #HealthcareInnovation To view or add a comment, sign in Day 41 of Understanding Healthcare Business 48% price cut
We are in a strategic location for your convenience
Our Take Most athletes default to coffee or energy drinks when they need to switch on fast